Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Expertise in Breast Neoplasms: HELP
Graham Ross
Based on 9 articles published since 2009
(Why 9 articles?)
||||
Expertise Level
The expertise of Graham Ross ranks in the
  • Top 1.5%
  • ... of 287,191 published authors worldwide on Breast Neoplasms
  • ... from 2009 through 2019
  • ... based on contributions to 9 articles on the topic.
Graphical view (beta)
Work Locations
Details
Most likely:    Hoffman-La Roche      
2016
  • Oncologia Medica, San Raffaele Cancer Centre, Milan, Italy. Electronic address: · Postgraduate Medical Education Centre, Warsaw, Poland. · Samsung Medical Centre, Seoul, South Korea. · Taipei-Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan. · Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan. · Hospital Clínico Universitario, INCLIVA Health Research Institute, University of Valencia, Valencia, Spain. · St John's Cancer Centre, Lublin, Poland. · Oncology Department, Maimonides Institute of Biomedical Research, Reina Sofía Hospital, University of Córdoba, Córdoba, Spain. · Division of Hematology/Medical Oncology, Department of Internal Medicine, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea. · Hospital Nossa Senhora da Conceição, Hospital Ernesto Dornelles, Porto Alegre, Brazil. · Hôpital du Saint-Sacrément, Centre Hospitalier Affilié Universitaire de Québec, Québec, Canada. · Medical Oncology Department, Ospedale dell'Angelo Mestre, Ospedale San Giovanni e Paolo Venezia, Venice, Italy. · N N Petrov Research Institute of Oncology, St Petersburg, Russia. · Medical Oncology Unit, Department of Medicine, Siriraj Hospital, Bangkok, Thailand. · Oncologia Medica 1, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy. · Fondazione Michelangelo, Milan, Italy. · Roche Products Limited, Welwyn, UK. · Roche Products Limited, Welwyn, UK; AstraZeneca, Melbourn, Cambridge, UK. · Pubmed 27179402
2014
  • José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY · Javier Cortés, Vall d'Hebron University Hospital, Barcelona, Spain · Seock-Ah Im, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea · Emma Clark and Graham Ross, Roche Products, Welwyn Garden City, United Kingdom · Astrid Kiermaier, F. Hoffmann-La Roche, Basel, Switzerland · and Sandra M. Swain, Washington Cancer Institute, MedStar Washington Hospital Center, Washington, DC. · Pubmed 25332247
2014
  • Washington Cancer Institute, MedStar Washington Hospital Center, Washington, D.C., USA; Division of Hematology and Medical Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; Division of Hematology and Medical Oncology, Department of Internal Medicine, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea; Veterans Memorial Medical Center, Cancer Research Center, Quezon City, Philippines; Mount Vernon Cancer Centre, Middlesex, United Kingdom; Roche Products Ltd., Welwyn Garden City, United Kingdom; Memorial Sloan-Kettering Cancer Center, Memorial Hospital, New York, New York, USA · Washington Cancer Institute, MedStar Washington Hospital Center, Washington, D.C., USA; Division of Hematology and Medical Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; Division of Hematology and Medical Oncology, Department of Internal Medicine, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea; Veterans Memorial Medical Center, Cancer Research Center, Quezon City, Philippines; Mount Vernon Cancer Centre, Middlesex, United Kingdom; Roche Products Ltd., Welwyn Garden City, United Kingdom; Memorial Sloan-Kettering Cancer Center, Memorial Hospital, New York, New York, USA. · Pubmed 24869931
Probable:    AstraZeneca      
2016
  • Oncologia Medica, San Raffaele Cancer Centre, Milan, Italy. Electronic address: · Postgraduate Medical Education Centre, Warsaw, Poland. · Samsung Medical Centre, Seoul, South Korea. · Taipei-Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan. · Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan. · Hospital Clínico Universitario, INCLIVA Health Research Institute, University of Valencia, Valencia, Spain. · St John's Cancer Centre, Lublin, Poland. · Oncology Department, Maimonides Institute of Biomedical Research, Reina Sofía Hospital, University of Córdoba, Córdoba, Spain. · Division of Hematology/Medical Oncology, Department of Internal Medicine, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea. · Hospital Nossa Senhora da Conceição, Hospital Ernesto Dornelles, Porto Alegre, Brazil. · Hôpital du Saint-Sacrément, Centre Hospitalier Affilié Universitaire de Québec, Québec, Canada. · Medical Oncology Department, Ospedale dell'Angelo Mestre, Ospedale San Giovanni e Paolo Venezia, Venice, Italy. · N N Petrov Research Institute of Oncology, St Petersburg, Russia. · Medical Oncology Unit, Department of Medicine, Siriraj Hospital, Bangkok, Thailand. · Oncologia Medica 1, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy. · Fondazione Michelangelo, Milan, Italy. · Roche Products Limited, Welwyn, UK. · Roche Products Limited, Welwyn, UK; AstraZeneca, Melbourn, Cambridge, UK. · Pubmed 27179402
Show More
Specific Interests

In the titles of their published articles, experts often reveal their very specific interests.

Here are the titles of all articles written by Graham Ross in 2009-2019 about Breast Neoplasms:

  • 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. 2016
  • Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. 2015
  • Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. 2014
  • Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRA. 2014
  • Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy: an exploratory analysis of the TRYPHAENA study. 2014
  • Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA). 2013
  • Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxel. 2013
  • Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. 2013
  • Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study. 2013
Show List of Full Article Records
Google Searches

Learn more about Graham Ross using the ready-made Google searches below.
This is essential! -- Publications never tell the whole story!

General Search:
Hoffman-La Roche
AstraZeneca
Affiliation Timeline
Click for institutional directory in table below. (Not always available.)
What is this?
Hoffman-La Roche
2016
  • Oncologia Medica, San Raffaele Cancer Centre, Milan, Italy. Electronic address: · Postgraduate Medical Education Centre, Warsaw, Poland. · Samsung Medical Centre, Seoul, South Korea. · Taipei-Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan. · Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan. · Hospital Clínico Universitario, INCLIVA Health Research Institute, University of Valencia, Valencia, Spain. · St John's Cancer Centre, Lublin, Poland. · Oncology Department, Maimonides Institute of Biomedical Research, Reina Sofía Hospital, University of Córdoba, Córdoba, Spain. · Division of Hematology/Medical Oncology, Department of Internal Medicine, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea. · Hospital Nossa Senhora da Conceição, Hospital Ernesto Dornelles, Porto Alegre, Brazil. · Hôpital du Saint-Sacrément, Centre Hospitalier Affilié Universitaire de Québec, Québec, Canada. · Medical Oncology Department, Ospedale dell'Angelo Mestre, Ospedale San Giovanni e Paolo Venezia, Venice, Italy. · N N Petrov Research Institute of Oncology, St Petersburg, Russia. · Medical Oncology Unit, Department of Medicine, Siriraj Hospital, Bangkok, Thailand. · Oncologia Medica 1, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy. · Fondazione Michelangelo, Milan, Italy. · Roche Products Limited, Welwyn, UK. · Roche Products Limited, Welwyn, UK; AstraZeneca, Melbourn, Cambridge, UK. · Pubmed 27179402
2014
  • José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY · Javier Cortés, Vall d'Hebron University Hospital, Barcelona, Spain · Seock-Ah Im, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea · Emma Clark and Graham Ross, Roche Products, Welwyn Garden City, United Kingdom · Astrid Kiermaier, F. Hoffmann-La Roche, Basel, Switzerland · and Sandra M. Swain, Washington Cancer Institute, MedStar Washington Hospital Center, Washington, DC. · Pubmed 25332247
2014
  • Washington Cancer Institute, MedStar Washington Hospital Center, Washington, D.C., USA; Division of Hematology and Medical Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; Division of Hematology and Medical Oncology, Department of Internal Medicine, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea; Veterans Memorial Medical Center, Cancer Research Center, Quezon City, Philippines; Mount Vernon Cancer Centre, Middlesex, United Kingdom; Roche Products Ltd., Welwyn Garden City, United Kingdom; Memorial Sloan-Kettering Cancer Center, Memorial Hospital, New York, New York, USA · Washington Cancer Institute, MedStar Washington Hospital Center, Washington, D.C., USA; Division of Hematology and Medical Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; Division of Hematology and Medical Oncology, Department of Internal Medicine, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea; Veterans Memorial Medical Center, Cancer Research Center, Quezon City, Philippines; Mount Vernon Cancer Centre, Middlesex, United Kingdom; Roche Products Ltd., Welwyn Garden City, United Kingdom; Memorial Sloan-Kettering Cancer Center, Memorial Hospital, New York, New York, USA. · Pubmed 24869931
AstraZeneca
2016
  • Oncologia Medica, San Raffaele Cancer Centre, Milan, Italy. Electronic address: · Postgraduate Medical Education Centre, Warsaw, Poland. · Samsung Medical Centre, Seoul, South Korea. · Taipei-Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan. · Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan. · Hospital Clínico Universitario, INCLIVA Health Research Institute, University of Valencia, Valencia, Spain. · St John's Cancer Centre, Lublin, Poland. · Oncology Department, Maimonides Institute of Biomedical Research, Reina Sofía Hospital, University of Córdoba, Córdoba, Spain. · Division of Hematology/Medical Oncology, Department of Internal Medicine, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea. · Hospital Nossa Senhora da Conceição, Hospital Ernesto Dornelles, Porto Alegre, Brazil. · Hôpital du Saint-Sacrément, Centre Hospitalier Affilié Universitaire de Québec, Québec, Canada. · Medical Oncology Department, Ospedale dell'Angelo Mestre, Ospedale San Giovanni e Paolo Venezia, Venice, Italy. · N N Petrov Research Institute of Oncology, St Petersburg, Russia. · Medical Oncology Unit, Department of Medicine, Siriraj Hospital, Bangkok, Thailand. · Oncologia Medica 1, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy. · Fondazione Michelangelo, Milan, Italy. · Roche Products Limited, Welwyn, UK. · Roche Products Limited, Welwyn, UK; AstraZeneca, Melbourn, Cambridge, UK. · Pubmed 27179402
12 Other Locations Show
Yearly article counts 00011340000
 
Remember this Person You can save this page -- like a bookmark -- so it's remembered for you on the Expertscape "Saved Pages" page, which is always easily available from the page-top menu bar throughout the site.